From Clinical Trials to Community Practice: Contextualizing Lorlatinib's Durability and Implementing Long-Term Management Strategies

This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to earlier ALK inhibitors, and the practical, multidisciplinary strategies clinicians need to support patients on long-term therapy — while making a compelling case for why these data are directly relevant to community oncology practice. Dr. Shaw opens by contextualizing the landmark finding that 55% of patients were alive and progression-free at 7 years, tracing the generational arc of ALK inhibitor development. First-generation crizotinib yielded a median PFS of 9 to 10 months — remarkable for its time. Second-generation agents including alectinib, brigatinib, and ensartinib advanced that benchmark to approximately 26 to 34 months. Lorlatinib's median PFS, now exceeding 7 years, represents a 2- to 3-fold improvement over those second-generation agents, an advance she describes as without parallel in lung cancer or any solid tumor.

The conversation then shifts to the practical question of how to keep patients on therapy long enough to realize that benefit. Dr. Shaw outlines her clinic's structured approach to side effect management, anchored by thorough upfront counseling — what she calls a “lorlatinib teach” — conducted with both the patient and their caregivers before the first dose is ever taken. Monitoring is intensive early on, with visits every 2 weeks in the first months, then monthly, gradually spacing to every 6 months for patients who have been stable for years. For persistent long-term side effects such as edema and weight gain, she emphasizes dietary modification, structured exercise, and referral to a nutritionist, while also noting emerging interest in GLP-1 agonists as a potential tool for weight management — though robust data remain forthcoming.

The segment closes with a clear message for community oncologists: given the strength of the CROWN data, first-line lorlatinib should be the default choice for most patients with advanced ALK-positive NSCLC, with only specific clinical circumstances — such as significant frailty or pre-existing psychiatric illness — warranting a different approach.